Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT04487548 |
Other study ID # |
FHREB 2017-099 |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
February 24, 2022 |
Est. completion date |
January 1, 2024 |
Study information
Verified date |
September 2023 |
Source |
Fraser Health |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Smoking continues to be a burden to the healthcare system in Canada. It is well-known that
smokers suffer more complications and higher risk of mortality after surgery than
non-smokers. A quality improvement project at Royal Columbian Hospital recently showed that
it is possible to implement a smoking cessation bundle for all current smokers during their
preadmission clinic visit. However, due to the COVID-19 pandemic, much of the bundle was
abandoned as it relied heavily on in-person interactions. The investigators wish to study the
effect of a structured smoking cessation bundle, delivered remotely, on smoking cessation and
postoperative complications. The aim is to determine the feasibility of giving the remotely
delivered bundle to elective surgical patients before or around the time of a preadmission
clinic visit, and whether it can reduce smoking rates and postoperative complications versus
the standard uncoordinated advice.
Description:
Introduction and Background Smoking continues to be a burden to the healthcare system in
Canada. As of 2019, 3.7 million Canadians (12% of the population over age 15) reported being
a current smoker. British Columbia's smoking rate is lower, but 10.2% of adults still
regularly smoke cigarettes1. It is well-known that smokers suffer more complications and
higher risk of mortality after surgery than non-smokers. Pulmonary complications,
cardiovascular complications, and surgical site infections are mediators of
smoking-associated mortality at 6-months and 1-year after elective surgery.
Although there have been a handful of studies that have demonstrated dramatic reductions in
postoperative complications with well-timed smoking cessation interventions in the
preoperative period, these results have not translated into widespread clinical practice in
delaying surgery for the purpose of achieving smoking cessation. In addition, most of these
studies took place in Europe, where smokers may behave differently than in the Canadian
setting.
A systematic review recommended at least 4 weeks of smoking cessation in order to reduce
postoperative complications6. Several European studies have shown dramatic reductions in
complications (up to 30% absolute risk reductions) when smoking cessation interventions have
been implemented 4-8 weeks preoperatively. One Canadian editorial even suggested new policies
be put into place to delay elective surgeries in smokers until a trial of cessation for 6
weeks had taken place.
Implementation of smoking cessation programs preoperatively have the potential to reduce
morbidity and mortality. A Cochrane systematic review has shown that preoperative smoking
cessation therapy improves both short and long-term smoking cessation. In fact, a surgical
encounter with the healthcare system has been described as a "teachable moment" that provides
motivation for patients to permanently stop smoking. Despite this information, most
anesthesiologists do not routinely offer smoking cessation advice to their patients and
advice, counselling, and pharmacotherapy for smoking cessation is not routine in
pre-admission clinics across Canada and the United States.
Several small trials have shown that smoking cessation interventions can increase smoking
cessation and reduce postoperative complications, particularly wound-healing complications,
which can have an absolute risk reduction of up to 25%. Prior work by one of the
co-investigators showed that a simple intervention in the pre-admission clinic was able to
increase the abstinence rate from 3.6% to 14.3% on the day of surgery. Smoking cessation
initiated in the perioperative period can also promote long-term smoking cessation.
Despite these successes, since the COVID-19 pandemic, standard care at Royal Columbian
Hospital (RCH) has not routinely included specific preoperative smoking cessation
pharmacotherapy or counselling. However, hospital leaders and the RCH Department of
Anesthesia have identified preoperative preparation, including smoking cessation, as a key
area of interest for development. Therefore, this is the ideal time to study the feasibility
of the perioperative smoking cessation bundle given to patients without the requirement for
an in-person visit. Advantages of this remote model are expected to continue after the
pandemic restrictions end, since smoking cessation bundles will be able to be started earlier
(and thus have more potential to prevent surgical complications), compared to waiting for a
preadmission clinic visit, which can often occur only a few days preoperatively. The
perioperative smoking cessation bundle will include: an emailed link to a quitnow.ca
preoperative smoking cessation video and referral to quit coach, free nicotine replacement
therapy (NRT) delivered by an online pharmacy, an emailed or post-mailed RCH smoking
cessation brochure, and brief telephone advice. This bundle will be offered to those regular
smokers of cigarettes randomized to the intervention group following their surgical
consultation, at the time of preadmission clinic appointment booking, or following their
preadmission telephone consultation. The control group will receive the standard of care
which sometimes includes brief advice and informing patients about availability of further
aids.
Once the simple smoking cessation intervention has been implemented for the intervention
group, the investigators wish to compare rates of resource access, smoking cessation, and
postoperative complications between the group receiving the smoking cessation bundle and
those receiving standard care. Due to the COVID-19 pandemic, in-person preadmission clinic
visits are no longer scheduled. Instead, high-risk surgical patients are phoned prior to
surgery to mitigate surgical risk factors and better prepare them for surgery.
Self-identification as a regular smoker is one risk factor that would warrant recruitment
into the study.
The investigators estimated that a definitive randomized controlled trial would require a
sample size of 214 participants. However, relatively low rates of smoking in British Columbia
and the cancellation of in-person preadmission clinic visits present a unique challenge to
patient recruitment. It is therefore imperative to establish the recruitment rate for
progression to a full randomized controlled trial.
Additionally, a preliminary analysis of rates of smoking and reduction of postoperative
complications in elective surgical patients when the smoking cessation bundle is given to
patients immediately following their preadmission clinic telephone consultation will be
conducted. The investigators plan to carry out a pilot randomized controlled trial where
patients who identify as smokers will be randomized to receive the remotely delivered smoking
cessation bundle versus standard care.
Purpose and Justification Most randomized studies showing improved smoking cessation rates
after preoperative interventions have strict inclusion and exclusion criteria, and required
ongoing consent for research experimentation, which limits their external generalizability.
The BuTT Out Pilot Study is of utmost importance since it has the potential to demonstrate
reductions in surgical site infections and lengths-of-stay using a low-cost intervention (a
bundle of emailed video, brochure, helpline referral and government funded smoking-cessation
therapy). A 2020 survey of the BC Smoking Cessation Program reported that 66% of respondents
found the program helpful, with a quit rate of 37%. Providing the program as a part of a
structured bundle will improve the accessibility of smoking cessation aids. If this
hypothesis is confirmed as suspected since it is based on prior research in other countries,
widespread implementation could translate into tremendous advantages for the patient, in
terms of reduced complications, and providers, in terms of cost savings. Conducting a pilot
study will help mitigate the challenge of recruiting an adequate sample size by establishing
a recruitment rate and consequently improve the feasibility of a definitive randomized
controlled trial. Since this study will examine remotely-delivered interventions, its
potential for widespread use will be much greater than other previously studied in-person
study designs.
Research Question For patients who smoke undergoing elective surgery, what is the effect of
an evidence-based remotely-delivered smoking cessation bundle administered preoperatively on
patients' outcomes (smoking rates, complication rates and hospital length of stay) compared
with standard practice which sometimes includes brief advice and informing patients about
availability of further aids?
Research Objectives To establish the recruitment rate, optimal recruitment pathway, and rate
of accessing of available resources as criteria for progression to a definitive randomized
controlled trial.
To determine whether smoking rates, surgical complications, and postoperative complications
can be documented in elective surgical patients when the remotely-delivered smoking cessation
bundle is administered preoperatively vs. standard care.
Research Hypothesis The hypothesis for this pilot RCT is that at least 8 patients will be
screened per week, at least 25% will give informed consent, and >80% will adhere to the study
protocol.
The overarching research hypothesis is that in patients who smoke, receiving the
remotely-delivered perioperative smoking cessation bundle prior to elective surgery for the
purpose of quitting smoking will result in reduced smoking rates on the day of surgery, lower
30-day complications, and shorter lengths of stay. Definitive estimation of effect size is
not expected from this pilot study, but confidence intervals will give rise to sample size
estimation for a future full-size trial.